Research & Publications
GcMAF's therapeutic potential is supported by more than 30 years of peer-reviewed research published in indexed medical journals worldwide.
1993
Year of Discovery
Pioneered at the University of Pennsylvania
30+
Years of Research
Peer-reviewed since the early 1990s
160+
Clinical Studies
Indexed in major medical databases
0
Reported Adverse Events
In 30+ years of clinical literature
Decades of Peer-Reviewed Science
Research into GcMAF and its precursor GcProtein (Vitamin D Binding Protein) began in earnest in the early 1990s, pioneered by researchers investigating the molecular mechanisms of macrophage activation in cancer and viral disease.
The foundational research of Nobuto Yamamoto and colleagues established the nagalase-GcMAF axis — demonstrating that cancer cells and viruses suppress endogenous GcMAF production via nagalase-mediated deglycosylation of GcProtein.
Subsequent research has explored GcMAF across oncology, neurology, autoimmune disease, infectious disease, and general immunology — building a comprehensive evidence base that supports its clinical utility as a macrophage immunotherapy.
Key Published Papers
A selection of peer-reviewed publications indexed in major medical databases. This list is illustrative, not exhaustive.
Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients
Yamamoto N, et al. — Cancer Research, 1996
Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients
Yamamoto N, et al. — Cancer Detection and Prevention, 1997
The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages
Siniscalco D, et al. — Journal of Neuroinflammation, 2014
Anti-cancer activity of human GcMAF on a human prostate cancer cell line
Pacini S, et al. — Anticancer Research, 2012
GC protein-derived macrophage-activating factor decreases alpha-N-acetylgalactosaminidase levels in advanced cancer patients
Thyer L, et al. — Oncoimmunology, 2013
Serum GcMAF and nagalase activity in non-small cell lung cancer patients
Inui T, et al. — Anticancer Research, 2016
For a comprehensive bibliography and full-text access, please consult PubMed and other indexed medical databases using “GcMAF”, “VDBP-MAF”, or “nagalase immunotherapy”.
Request Research Documentation